Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: a continuous infusion PET study in conscious monkeys

Synapse. 2006 Jan;59(1):18-26. doi: 10.1002/syn.20209.

Abstract

[(18)F]MPPF is a selective and reversible antagonist to the serotonin-1A (5-HT(1A)) receptor. The aim of the present study was to investigate whether the binding of [(18)F]MPPF is sensitive to increases in 5-HT levels. We used the 5-HT releasing agent and reuptake inhibitor fenfluramine (FEN) to increase the concentration of 5-HT. [(18)F]MPPF binding was assessed using positron emission tomography (PET) in conscious monkeys. Possible effects of blood flow on ligand binding were excluded by using a bolus-infusion paradigm. Control scans were obtained to assess the state of ligand equilibrium. FEN (5 or 10 mg/kg, i.v.) was administered between 90 and 130 min after the start of the [(18)F]MPPF infusion. The binding potential (BP) was calculated for an early interval (30 min preceding FEN administration) and late interval (20-50 min after administration of FEN). Microdialyses results showed a 20- and 35-fold increase in extracellular 5-HT levels in the prefrontal cortex after injection of FEN at a dose of 5 mg/kg and 10 mg/kg respectively. However, despite these large increases in 5-HT levels, no differences in BP were found between the control and FEN scans. These results may imply that the majority of 5-HT(1A) receptors is in the low affinity state in the living brain.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoradiography
  • Brain / anatomy & histology
  • Brain / diagnostic imaging
  • Brain / drug effects*
  • Brain / metabolism
  • Brain Chemistry / drug effects
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Fenfluramine / pharmacology*
  • Macaca mulatta
  • Magnetic Resonance Imaging / methods
  • Male
  • Microdialysis / methods
  • Piperazines / pharmacokinetics*
  • Positron-Emission Tomography*
  • Protein Binding / drug effects
  • Pyridines / pharmacokinetics*
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Serotonin / metabolism*
  • Time Factors
  • Wakefulness

Substances

  • Piperazines
  • Pyridines
  • Serotonin Uptake Inhibitors
  • Fenfluramine
  • Serotonin
  • 4-(2'-methoxyphenyl)-1-(2'-(N-2'-pyridinyl)-p-(18F)fluorobenzamido )ethylpiperazine